Meeting
2023 ASCO Annual Meeting
A phase II study of palbociclib combined with retifanlimab in patients with advanced dedifferentiated liposarcoma.
Authors
Sandra P. D'Angelo
Memorial Sloan Kettering Cancer Center, New York, NY
Sandra P. D'Angelo , Evan Rosenbaum , Rodrigo Gularte Mérida , Mark Andrew Dickson , Mary Louise Keohan , Mrinal M. Gounder , Ping Chi , Sujana Movva , Ciara Marie Kelly , Viswatej Avutu , Jason Earl Chan , Jae Cho , Matthew Biniakewitz , Grace Cho , Joseph Patrick Erinjeri , Robert A Lefkowitz , Cristina R. Antonescu , Li-Xuan Qin , Samuel Singer , William D. Tap
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT04438824
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS11590)
DOI
10.1200/JCO.2023.41.16_suppl.TPS11590
Abstract #
TPS11590
Poster Bd #
518b
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
BLU-222, an oral, potent, and selective CDK2 inhibitor, in patients with advanced solid tumors: Phase 1 monotherapy dose escalation.
First Author: Manish R. Patel
Poster
2024 ASCO Annual Meeting
TACTIVE-K: Phase 1b/2 study of vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, in combination with PF-07220060, a cyclin-dependent kinase (CDK)4 inhibitor, in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer.
First Author: Melinda L. Telli
Poster
2023 ASCO Annual Meeting
A phase I trial of palbociclib (palbo) and bosutinib (bos) with fulvestrant (fulv) in patients (pts) with hormone receptor–positive, HER2-negative (HR+/HER2-) metastatic breast cancer (MBC) refractory to an aromatase inhibitor (AI) and a CDK4/6 inhibitor (CDK4/6i).
First Author: Candace Bavette Mainor
Poster
2023 ASCO Annual Meeting
Updated results from a phase 2 study on dalpiciclib and pyrotinib, a dual-oral chemotherapy-free regimen in HER2-positive advanced breast cancer (DAP-HER-01).
First Author: Min Yan